The antiserum was produced against synthesized peptide derived from human Src around the phosphorylation site of Ser75. AA range:41-90

Phospho-c-Src (S75) Polyclonal Antibody detects endogenous levels of c-Src protein only when phosphorylated at S75.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):VTsPQ

SRC SRC1

Proto-oncogene tyrosine-protein kinase Src

SRC ;
SRC1 ;
Proto-oncogene tyrosine-protein kinase Src ;
Proto-oncogene c-Src ;
pp60c-src ;
p60-Src

This gene is highly similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the regulation of embryonic development and cell growth. The protein encoded by this gene is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by c-SRC kinase. Mutations in this gene could be involved in the malignant progression of colon cancer. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008],

Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,PTM:Phosphorylated on Tyr-530 by c-Src kinase (CSK). The phosphorylated form is termed pp60c-src. The phosphorylated tail interacts with the SH2 domain thereby repressing kinase activity.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 SH2 domain.,similarity:Contains 1 SH3 domain.,subunit:Interacts with DDEF1/ASAP1; via the SH3 domain. Interacts with CCPG1 (By similarity). Interacts with CDCP1, PELP1, TGFB1I1 and TOM1L2. Interacts with the cytoplasmic domain of MUC1, phosphorylates it and increases binding of MUC1 with beta-catenin. Interacts with RALGPS1; via the SH3 domain. Interacts with HEV ORF3 protein; via the SH3 domain.,

Cell membrane ; Lipid-anchor . Mitochondrion inner membrane . Nucleus . Cytoplasm, cytoskeleton . Cytoplasm, perinuclear region . Cell junction, focal adhesion . Localizes to focal adhesion sites following integrin engagement (PubMed:22801373). Localization to focal adhesion sites requires myristoylation and the SH3 domain (PubMed:7525268). Colocalizes with PDLIM4 at the perinuclear region, but not at focal adhesions (PubMed:19307596). .

>>EGFR tyrosine kinase inhibitor resistance ;
>>Endocrine resistance ;
>>ErbB signaling pathway ;
>>Rap1 signaling pathway ;
>>Chemokine signaling pathway ;
>>Mitophagy - animal ;
>>Endocytosis ;
>>Axon guidance ;
>>VEGF signaling pathway ;
>>Focal adhesion ;
>>Adherens junction ;
>>Tight junction ;
>>Gap junction ;
>>Platelet activation ;
>>Neutrophil extracellular trap formation ;
>>C-type lectin receptor signaling pathway ;
>>GABAergic synapse ;
>>Inflammatory mediator regulation of TRP channels ;
>>Regulation of actin cytoskeleton ;
>>GnRH signaling pathway ;
>>Estrogen signaling pathway ;
>>Prolactin signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Oxytocin signaling pathway ;
>>Relaxin signaling pathway ;
>>Bacterial invasion of epithelial cells ;
>>Epithelial cell signaling in Helicobacter pylori infection ;
>>Pathogenic Escherichia coli infection ;
>>Shigellosis ;
>>Yersinia infection ;
>>Tuberculosis ;
>>Hepatitis B ;
>>Human cytomegalovirus infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Viral carcinogenesis ;
>>Proteoglycans in cancer ;
>>Chemical carcinogenesis - receptor activation ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Bladder cancer ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis